Clinical trial
Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine…
NCT00159471 · University of Southern California, Other · Terminated
Key facts
| NCT number | NCT00159471 |
|---|---|
| Title | Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer. |
| Official title | A Pilot Trial of Germline Polymorphisms as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer. |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Sanofi Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gemcitabine, docetaxel |
| Enrollment | 1 |
| Start date | Feb 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: